Abbott Laboratories
ABT
Unten findest du den Live-Kurs für Abbott Laboratories (ABT), einen 1-Jahres-Chart, 8 Indikatoren (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volumen) und einen Vergleichsmodus. Hinzufügen zum Portfolio, auf die Beobachtungsliste setzen oder einen Preisalarm einrichten — alles in einem.
Abbott Laboratories (ABT) ist ein in United States ansässiges Healthcare-Unternehmen. Tätig in der Branche Medical Devices, beschäftigt rund 122,000 Mitarbeiter:innen. Im vergangenen Jahr bewegte sich ABT zwischen 81.97 und 137.49 USD. Das Trailing-KGV liegt bei rund 28.2, die Marktkapitalisierung bei etwa 175.37B USD. Aktuell wirft die Aktie eine Dividendenrendite von 2.50 % ab.
- Prev close
- $98.83
- Volume (24h)
- $1.72B
- Market cap
- $175.37B
- Currency
- USD
Bewertung
49/ 100 · Gemischt
- Wert52
- Qualität74
- Momentum21
- Wachstum24
- Risiko79
- Dividende42
- Liquidität—
Komposit aus öffentlichen Marktdaten. Nur zur Information — keine Anlageberatung.
Trendprojektion
Wohin der jüngste Trend zeigt, wenn er sich fortsetzt.
- +5 Bars
- 101.1581 +0.47%
- +20 Bars
- 101.8216 +1.13%
- +60 Bars
- 102.0795 +1.39%
- +120 Bars
- 102.0889 +1.40%
Lineare Regressions-Fortschreibung — keine Vorhersage, keine Anlageberatung. ±1σ ≈ 68% · ±2σ ≈ 95%: ±0.0352 USD.
Interpretation
Die zusammengesetzten Signale wirken gemischt. Stärke: Risikoprofil mit schwäche: momentum. Kurs liegt im oberen Drittel der jüngsten Spanne, Trend zeigt nach oben.
Beschreibende Beobachtung — keine Anlageberatung.
Bewertungs-Aufschlüsselung
Die Rohwerte hinter jedem Pillar — so siehst du, was die zusammengesetzte Bewertung liest.
- Wert52/100
Wert wirkt gemischt — getragen von KGV (28.2).
KGV:28.2KBV:3.37PEG:1.5 - Qualität74/100
Qualität wirkt solide — getragen von Bruttomarge (56.77%).
Nettomarge:11.65%Bruttomarge:56.77% - Momentum21/100
Momentum wirkt fragil — getragen von 52-Wo. Veränderung (-19.08%).
52-Wo. Veränderung:-19.08% - Wachstum24/100
Wachstum wirkt fragil — getragen von EPS-Wachstum (-47.50%).
Umsatzwachstum:13.00%EPS-Wachstum:-47.50% - Risiko79/100
Risiko wirkt stark — getragen von Verschuldungsgrad (64.77).
Beta:0.61Verschuldungsgrad:64.77Leerverkaufsquote:1.50% - Dividende42/100
Dividende wirkt schwach — getragen von Ausschüttungsquote (67.23%).
Dividendenrendite:2.50%Ausschüttungsquote:67.23%
Abgeleitet aus öffentlichen Marktdaten — informativ, keine Anlageberatung.
Referenzniveaus
Fibonacci-Retracements und -Extensions im jüngsten Bereich.
Nur Referenz — keine Anlageberatung.
Diese Koordinaten beschreiben Preisballungen aus der Vergangenheit, nicht wo gekauft oder verkauft werden sollte. Recherchiere selbst, bevor du handelst.
- ResistanceFib-Extension +161.8%134.7489 USD+33.84% vom aktuellen Kurs
- ResistanceFib-Extension +100%122.29 USD+21.46% vom aktuellen Kurs
- ResistanceFib-Extension +61.8%114.5889 USD+13.81% vom aktuellen Kurs
- ResistanceFib-Extension +27.2%107.6135 USD+6.89% vom aktuellen Kurs
- Aktuell100.68 USD
- SupportFib-Retracement 23.6%97.3722 USD-3.29% vom aktuellen Kurs
- SupportFib-Retracement 38.2%94.4289 USD-6.21% vom aktuellen Kurs
- SupportFib 50% Mittelpunkt92.05 USD-8.57% vom aktuellen Kurs
- SupportFib-Retracement 61.8%89.6711 USD-10.93% vom aktuellen Kurs
- SupportFib-Retracement 78.6%86.2842 USD-14.30% vom aktuellen Kurs
- SupportFib-Extension −27.2%76.4865 USD-24.03% vom aktuellen Kurs
- SupportFib-Extension −61.8%69.5111 USD-30.96% vom aktuellen Kurs
- SupportFib-Extension −100%61.81 USD-38.61% vom aktuellen Kurs
Financials
- 52w high
- $137.49
- 52w low
- $81.97
- 52w change
- -19.08%
- Day high
- $102.13
- Day low
- $99.47
- P/E (TTM)
- 28.2
- Forward P/E
- 16.6
- PEG
- 1.5
- Price / Book
- 3.37
- Beta (5Y)
- 0.61
- Enterprise value
- 202.85B
- EV / Revenue
- 4.35
- EV / EBITDA
- 17.09
- EPS (TTM)
- $3.57
- Forward EPS
- $6.07
- Dividend yield
- 2.50%
- Dividend rate
- $2.52
- Payout ratio
- 67.23%
- Revenue (TTM)
- 46.58B
- EBITDA
- 11.87B
- Total cash
- 7.3B
- Total debt
- 34.14B
- Debt / Equity
- 64.77
- Profit margin
- 11.65%
- Gross margin
- 56.77%
- Shares outstanding
- 1.74B
- Float
- 1.73B
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Analyst & Risk
- Beta (vs S&P 500)
- 0.61
- less volatile
- 52-week change
- -19.08%
- Short % of float
- 1.50%
- Short ratio (days)
- 1.67
- Debt / Equity
- 64.77
- very high leverage
- PEG ratio
- 1.5
- fair
- EV / Revenue
- 4.35
- EV / EBITDA
- 17.09
- Revenue growth
- 13.00%
- Earnings growth
- -47.50%
- EBITDA
- 11.87B
- Total cash
- 7.3B
- Total debt
- 34.14B
- Insider holdings
- 0.49%
- Institutional
- 82.43%
Recent rating changes
- 2026-07-17CitigroupBuy → Buymain
- 2026-07-17Piper SandlerOverweight → Overweightreit
- 2026-07-17JP MorganOverweight → Overweightmain
- 2026-07-17Wells FargoOverweight → Overweightmain
- 2026-07-17TD CowenBuy → Buyreit
- 2026-07-17Evercore ISI GroupOutperform → Outperformmain
- 2026-07-17RBC CapitalOutperform → Outperformreit
- 2026-07-17BTIGBuy → Buymain
Financial documents
- Corporate Changes & Voting Matters8-K2026-07-16
- Annual report of employee stock purchase11-K2026-06-18
- Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)SD2026-05-27
- Periodic Financial Reports10-Q2026-04-29
- Corporate Changes & Voting Matters8-K2026-04-27
- Offering RegistrationsS-82026-04-24
- Corporate Changes & Voting Matters8-K2026-04-17
- Corporate Changes & Voting Matters8-K2026-04-16
- Offering RegistrationsS-82026-03-23
- Proxy StatementsDEFA14A2026-03-13
- Corporate Changes & Voting Matters8-K2026-03-09
- Corporate Changes & Voting Matters8-K2026-02-26
Aktuelle Nachrichten
- My 2 Favorite Dividend Kings to Buy Right NowMotley Fool13h ago
- The Justice Department Is Pulling Back on Prosecuting Corporate CrimeThe Wall Street Journal1d ago
- ABT Q2 Earnings Call Flags Stronger Second-Half SetupZacks2d ago
- Abbott Laboratories Seen on Track for H2 Growth Acceleration, RBC SaysMT Newswires2d ago
- BTIG Adjusts Price Target on Abbott Laboratories to $134 From $131, Maintains Buy RatingMT Newswires2d ago
- Piper Sandler Adjusts Price Target on Abbott Laboratories to $118 From $115, Maintains Overweight RatingMT Newswires2d ago
- JPMorgan Adjusts Price Target on Abbott Laboratories to $120 From $110, Maintains Overweight RatingMT Newswires2d ago
- Evercore ISI Adjusts Price Target on Abbott Laboratories to $120 From $112, Maintains Outperform RatingMT Newswires2d ago
Verwandt
Weitere Assets in dieser Kategorie.
- 8306.TMitsubishi UFJ Financial Group, Inc.3,473 USD-4.30%
- 7203.TToyota Motor Corporation2,899.5 USD-0.33%
- 9984.TSoftBank Group Corp.5,424 USD-9.01%
- 6758.TSony Group Corporation3,470 USD+0.93%
- 6861.TKeyence Corporation70,880 USD-4.28%
- NVDANVIDIA Corporation202.81 USD-2.21%
- AAPLApple Inc.333.74 USD+0.14%
- 0700.HKTencent Holdings Limited477.8 USD+3.51%
Live-Diskussion
Anmelden to join the discussion.
- Noch keine Kommentare. Sei der Erste.